Melanoma - Pipeline Insight, 2024

Melanoma - Pipeline Insight, 2024

DelveInsight’s, “Melanoma- Pipeline Insight, 2024,”report provides comprehensive insights about 150+ companies and 170+ pipeline drugs in Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Melanoma Understanding

Melanoma: Overview

Melanoma is considered as a type of cancer that develops in the pigment-producing melanocyte cells. Anyway, tumors will grow in melanocytes of the skin in almost 90% of cases; it can also occur in melanocytes of the eye, internal organs, and mucosal membranes lining the gastrointestinal, respiratory and urogenital tracts. Melanoma is the third most common cutaneous malignancy after basal cell carcinoma and squamous cell carcinoma. Melanoma is the fifth most common malignancy in males and sixth most common malignancy in females. It is considered one of the most challenging diseases to treat with pharmacotherapy; melanoma drug development lagged than many other cancers, going on in decades with limited progress.

Common melanoma metastasis sites include the lymph nodes, lungs, liver, bones and brain. Common symptoms of melanoma includes a new, unusual growth or a change in an existing mole the person may experience bigger mole diameter, darkening of the skin, mole color changes, or skin mole with irregular border, a skin sore that fails to heal, a spot or sore that becomes painful, itchy, or tender melanomas can occur anywhere on the body. During diagnosing with melanoma, doctor will do a skin exam and also the ABCDE examination. If they think patient may have skin cancer, patient would need a biopsy to find out. Usually gets one of three types: Punch biopsy. This removes a round piece of skin. Excisional biopsy: doctor takes out the entire growth. Shave biopsy: doctor tries to shave off the entire growth. A doctor will look at the growth under a microscope to see how thick it is. Usually, a thicker tumor means there is a higher risk the cancer will spread. Additional tests are needed to determine whether the cancer is metastatic melanoma, or if there’s no visible primary tumor.

There are various methods to diagnose the melanoma that includes sentinel lymph node biopsy, CT-Scans, MRI Scan, and PET scan, blood tests may be used to measure lactate dehydrogenase (LDH) before treatment. Other tests include blood chemistry levels and blood cell counts. Melanoma treatment depends on the current stage of the melanoma and general health of the person. Treatments for this disease includes melanoma surgery in early stages, surgery has a high probability of being able to cure the melanoma. Lymphadenectomy in cases where melanoma has spread, removal of the lymph nodes near the primary diagnosis site may be required this can prevent the spread to other areas of the body. Metastasectomy is used to remove small melanoma bits from organs. Targeted cancer therapy in this treatment option, drugs are used to attack specific cancer cells. Radiation therapy is also opted by many doctors and lastly the immunotherapy which is adopted by many biopharma companies for the treatment of melanoma.

""Melanoma- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Melanoma pipeline landscape is provided which includes the disease overview and Melanoma treatment guidelines. The assessment part of the report embraces, in depth Melanoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Melanoma R&D. The therapies under development are focused on novel approaches to treat/improve Colorectal Cancer.

Melanoma Emerging Drugs Chapters

This segment of the Melanoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Melanoma Emerging Drugs

• IO102 IO103 : IO Biotech

IO102-IO103 is an investigational immune-modulating therapeutic cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1). IDO and/or PD-L1 are overexpressed by many types of solid tumors and immune-suppressive cells (Tregs and TAMs) in the TME. The company is developing this vaccine based on its T-win® vaccine platform. Currently it is in Phase III stage of clinical trial evaluation to treat Melanoma.

• mRNA 4157: Moderna Inc.

mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient's tumor. The drug is been developed jointly by Moderna & Merck. Currently being evaluated in the Phase III studies.

• MK-4830: Merck Sharp & Dohme LLC

MK-4830 is an investigational monoclonal antibody that inhibits the binding of Immunoglobulin-like transcript 4 (ILT-4) to its ligands. The drug candidate is being developed in combination with KEYTRUDA. MK-4830 is being developed under an agreement with Agenus Inc. Currently the drug is being evaluated in Phase II for the treatment of Colorectal Cancer.

• BNT111: BioNTech SE

BNT111 is an intravenous therapeutic cancer immunotherapy candidate encoding a fixed set of four cancer-specific antigens optimized for immunogenicity and delivered as RNA-lipoplex formulation. The drug induces novel antigen-specific anti-tumor immune responses and enhances pre-existing immune responses against the encoded melanoma-associated antigens. The drug is in Phase II stage of clinical trials.

• TILT 123: TILT Biotherapeutics LLC

TILT-123 is a human 5/3 chimeric adenovirus that has been engineered to encode human Tumor Necrosis Factor alpha (hTNFa) and human Interleukin 2 (hIL-2) cytokines. It is optimized to generate an anti-cancer immune response by boosting the activity of T-cells and also stimulating other arms of the innate and adaptive immune system. TILT-123 can be administered by intravenous, intratumoral, intraperitoneal and intrapleural injection. The drug is in Phase I stage of clinical trials.

Further product details are provided in the report……..

Melanoma: Therapeutic Assessment

This segment of the report provides insights about the different Melanoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Melanoma

There are approx. 150+ key companies which are developing the therapies for Colorectal Cancer. The companies which have their Melanoma drug candidates in the most advanced stage, i.e. phase III include, IO Biotech

• Phases

Delve Insight’s report covers around 170+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Melanoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III II, I, preclinical and discovery stage. It also analyses Melanoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Melanoma drugs.

Melanoma Report Insights

• Melanoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Melanoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Melanoma drugs?
• How many Melanoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Melanoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Melanoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Melanoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• IO Biotech
• Moderna Inc.
• Merck Sharp & Dohme LLC
• BioNTech SE
• TILT Biotherapeutics LLC
• Nykode Therapeutics
• Achilles Therapeutics UK Limited
• Evaxion Biotech
• InxMed
• AiVita Biomedical
• Cytovation AS
• Ono Pharmaceuticals
• Neon Therapeutics
• Iovance Biotherapeutics

Key Products

• IO102 IO103
• mRNA 4157
• MK-4830
• BNT111
• TILT 123
• VB10 NEO
• LN-145-S1
• NEO-PV-01
• ONO4482
• BMS- 986249
• SEA-CD40